GSK Steps Up Parkinson’s Focus With US Biotech Deal
1 day ago · Listen. 1:49. GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug development for Parkinson’s disease. GSK will pay $80 ...
GSK pays Flagship biotech $80M for preclinical neuro pact
1 day ago · GSK inks Parkinson's pact with Flagship's Vesalius for $570M-plus biobucks. GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
GSK partners with Flagship startup to hunt for Parkinson’s drugs
2 days ago · The deal with GSK represents an upturn in fortune for Vesalius, which laid off 40% of its workforce in September 2022. Launched in 2019, the startup was co-founded by Christopher Austin, the former director of the National Institutes of Health’s National Center for Advancing Translational Sciences, and Doug Cole, a managing partner at Flagship. ...
Vesalius Announces Multi-Target Strategic Alliance with GSK to …
1 day ago · "GSK brings numerous strengths to this alliance including its global scale and expertise in human genetics," said Amanda Kay, Ph.D., Senior Partner and Chief Business Development Officer, Flagship ...
Health Canada approves GSK’s Ojjaara for ... - Yahoo Finance
19 hours ago · GSK. Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in adults with moderate-to-severe anaemia. The once-daily, oral ...
Press release archive - GSK
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
GSK invests up to $800 million in Pennsylvania site, largest ...
Oct 24, 2024 · The up to $800 million investment will bring state-of-the-art drug substance manufacturing and additional drug product manufacturing capabilities to the company’s site in Marietta, Pennsylvania, along with over 200 new jobs.
GSK (GSK) Q3 Earnings Surpass Estimates - Yahoo Finance
Oct 30, 2024 · GSK. GSK (GSK) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.26 per share a year ago. These figures ...
GSK makes a strong start to 2024 with improving outlook for the …
May 1, 2024 · Now expect 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% (previously 7% to 10%); Core EPS growth of 8% to 10% (previously 6% to 9%) Dividend declared of 15p for Q1 2024; 60p expected for Full Year 2024.
GSK delivers strong 2023 performance and upgrades growth …
Jan 31, 2024 · Broad-based performance drives sales, profits and earnings growth: Total 2023 sales £30.3 billion +5% and +14% ex COVID. Vaccines sales +25%, +24% ex COVID. Shingrix £3.4 billion +17%, Arexvy £1.2 billion.